Carcinoma, Transitional Cell: all 725 studies

Page 7 of 8. Open to participants first (201), then studies with results posted, then the rest; newest registration first within each.

• Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific GenesCompletedNCT02236195Phase 2
• Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the BladderActive, not recruitingNCT02202772Phase 1/2
• Dual Energy CT vs Standard Triple Phase CT-A Randomised Control TrialCompletedNCT02160600Not applicable
• A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder CancerActive, not recruitingNCT02138734Phase 1/2
• Alisertib in Chemotherapy-pretreated Urothelial CancerCompletedNCT02109328Phase 2
• A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of UrineCompletedNCT02101931Phase 3
• Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological CancersCompletedNCT02020707Phase 1
• Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid TumorsCompletedNCT02014337Phase 1
• A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT)Status unknownNCT01993979Phase 3
• EGCG Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma CellsStatus unknownNCT01993966
• The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial CarcinomaStatus unknownNCT01968928
• Adjuvant Radiation for High Risk Bladder CancerTerminatedNCT01954173Not applicable
• Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial CarcinomaWithdrawnNCT01907308Phase 2
• Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder CarcinomaCompletedNCT01878188Phase 1
• Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based ChemotherapyTerminatedNCT01856101Phase 2
• Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial TractCompletedNCT01844947Phase 1
• Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)Status unknownNCT01830231Phase 2/3
• Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial CarcinomaCompletedNCT01828736Phase 2
• Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder CancerCompletedNCT01824329Phase 2
• The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the UrotheliumCompletedNCT01801137Phase 2
• Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With CabazitaxelCompletedNCT01668459Phase 2/3
• Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial CancerWithdrawnNCT01639521Phase 2
• PF-03446962 in Relapsed or Refractory Urothelial CancerCompletedNCT01620970Phase 2
• Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial CarcinomaCompletedNCT01606345Phase 1
• A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC)CompletedNCT01600339Phase 2
• JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus CarboplatinCompletedNCT01599013Phase 2
• Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseTerminatedNCT01552434Phase 1
• Evaluation Of Zetiq's Novel Cell Detect Technology For Detection Of Bladder Cancer In Urine CytologyStatus unknownNCT01551342
• Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial CancerCompletedNCT01529411Phase 2
• Pemetrexed and Cisplatin in Advanced Urothelial CarcinomaCompletedNCT01490437Phase 2
• Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial CarcinomaStatus unknownNCT01487915Phase 2
• A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid TumorsCompletedNCT01478685Phase 1
• Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial CancerCompletedNCT01440998Phase 1
• Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder CancerTerminatedNCT01438112Phase 2/3
• Lymph Node Processing Protocol for Radical Cystectomy and Pelvic Lymph Node Dissection in Bladder CancerCompletedNCT01395225
• DNA Methylation and Urothelial CarcinomaStatus unknownNCT01378052
• Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney DysfunctionActive, not recruitingNCT01366144Phase 1
• DNA Methylation and Arsenic-associated Urothelial CarcinomaStatus unknownNCT01360723
• Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung CancerTerminatedNCT01282333Phase 1
• A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapyTerminatedNCT01234519Phase 1/2
• Tesetaxel for Previously Treated Patients With Bladder CancerStatus unknownNCT01215877Phase 2
• Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract CancerCompletedNCT01191892Phase 2
• The Expression and Effect of Cyr61 in Urinary Tract Transitional Cell CarcinomaStatus unknownNCT01189838
• B-Receptor Signaling in CardiomyopathyCompletedNCT01135849
• Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract CancerStatus unknownNCT01118039Phase 2
• JAVLOR® Online Non-Interventional TrialCompletedNCT01103544
• Prospective Multicentric Evaluation of a Bladder Preservation StrategyTerminatedNCT01093066Phase 2
• Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the UrotheliumCompletedNCT01090466Phase 1/2
• Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)CompletedNCT01089088Phase 2
• Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT01074411Phase 1
• Second-Line Docetaxel + ASA404 for Advanced Urothelial CarcinomaWithdrawnNCT01071928Phase 2
• Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to TreatmentCompletedNCT01031875Phase 2
• Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00989651Phase 1
• Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial CarcinomaTerminatedNCT00933374Phase 2
• Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy ParticipantsCompletedNCT00900276
• YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving ChemotherapyTerminatedNCT00899093
• Aristolochic Acid-DNA Adduct in Urothelial Carcinoma in TaiwanStatus unknownNCT00867633
• Development of a Non-Invasive DNA Methylation-Based Assay System for the Risk Assessment of Urothelial CarcinomaStatus unknownNCT00867620
• Arsenic Methylation Enzymes, Cigarette Metabolites, DNA Repair Enzymes, Inflammatory Factors and Urothelial CarcinomaStatus unknownNCT00854464
• Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell CancerCompletedNCT00792025Phase 2
• Phase II Study of TKI258 in Advanced Urothelial CarcinomaCompletedNCT00790426Phase 2
• Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United KingdomStatus unknownNCT00757614
• Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the UrotheliumActive, not recruitingNCT00756639Phase 2
• Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus unknownNCT00719303Phase 3
• A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of ChemotherapyCompletedNCT00714025Phase 2
• Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell CancerWithdrawnNCT00696007Phase 2
• Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of BladderCompletedNCT00694915Phase 2
• Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of BladderCompletedNCT00694798Phase 1
• Single Agent Abraxane as Second Line Therapy in Bladder CancerCompletedNCT00683059Phase 2
• Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor TypesCompletedNCT00633789Phase 2
• Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial CancerCompletedNCT00623064Phase 1
• Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and StagingCompletedNCT00612326
• Computed Tomography Urography (CTU) vs Intravenous Urography (IVU) on Patients at Risk of Urothelial TumorsActive, not recruitingNCT00567684Not applicable
• Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary BladderCompletedNCT00539773Not applicable
• A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816)CompletedNCT00536588Phase 1
• First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based TherapyCompletedNCT00389155Phase 2/3
• Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical ResectionCompletedNCT00362713Phase 1
• Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of BladderCompletedNCT00343356Phase 2
• Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.CompletedNCT00330499Phase 3
• Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial TractCompletedNCT00315237Phase 3
• Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the UrotheliumCompletedNCT00310011Phase 2
• Relationship of Ochratoxin A to Upper Urologic CancersCompletedNCT00216801
• 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP RegimenCompletedNCT00191971Phase 2
• Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCCCompletedNCT00173862Phase 2
• Chemoprevention Trial for Uremia-Associated Urothelial CarcinomaWithdrawnNCT00172367Phase 2
• Weekly TP-HDFL in the Treatment of Advanced TCCCompletedNCT00154687Phase 2
• Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder CancerStatus unknownNCT00146276Phase 3
• Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial TractTerminatedNCT00127595Phase 2
• Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) FailureStatus unknownNCT00109655Phase 1
• Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder CancerCompletedNCT00101842Phase 1/2
• Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the UrotheliumCompletedNCT00101608Phase 2
• S0400, FR901228 in Treating Patients With Advanced Cancer of the UrotheliumTerminatedNCT00087295Phase 2
• Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the UrotheliumCompletedNCT00080795Phase 2
• TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the UrotheliumCompletedNCT00077688Phase 2
• Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell CarcinomaCompletedNCT00072150Phase 2
• S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With ChemotherapyCompletedNCT00066612Phase 2
• Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or UreterCompletedNCT00066352Phase 2
• Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the UrotheliumCompletedNCT00053209Phase 2
• Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder CancerCompletedNCT00041106Phase 2
• A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the UrotheliumCompletedNCT00035061Phase 2

← Carcinoma, Transitional Cell overview